|Bid||62.89 x 1100|
|Ask||63.53 x 900|
|Day's Range||60.83 - 63.47|
|52 Week Range||43.37 - 107.69|
|Beta (5Y Monthly)||0.57|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 08, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||88.50|
Subscribe to Yahoo Finance Plus to view Fair Value for CSTLLearn more
FRIENDSWOOD, Texas, October 28, 2021--Castle announced that the Company's DecisionDx®-Melanoma integrated test result (ITR) now includes i31-GEP for Risk of Recurrence (i31-ROR).
FRIENDSWOOD, Texas, October 26, 2021--Castle announced a recent poster presentation on its DecisionDx® DiffDx™-Melanoma test at the ASDP 58th Annual Meeting.
Pittsburgh Life Science Greenhouse (PLSG) is proud to share that one of its portfolio companies, Cernostics, Inc., is being acquired by Castle Biosciences (Nasdaq: CSTL). Cernostics specializes in spatial biology and artificial intelligence-driven image analysis of tissue biopsies. Its TissueCypher® Barrett's Esophagus Assay is the first precision medicine test designed to predict future development of high-grade dysplasia (HGD) and/or esophageal cancer in patients with Barrett's esophagus (BE).